(Q40103316)

17 September 2017

Expression of erythropoietin and its receptor in neuroblastomas (English)

1 reference

17 September 2017

1 reference

10

Stefan Michiels

1 reference

17 September 2017

Hervé Sartelet

1

1 reference

17 September 2017

Monique Fabre

2

1 reference

17 September 2017

Marine Castaing

3

1 reference

17 September 2017

Jacques Bosq

4

1 reference

17 September 2017

Ivan Racu

5

1 reference

17 September 2017

Emeryc Lagonotte

6

1 reference

17 September 2017

Véronique Scott

7

1 reference

17 September 2017

Yann Lecluse

8

1 reference

17 September 2017

Stephane Barette

9

1 reference

17 September 2017

Gilles Vassal

11

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 September 2017

1 reference

17 September 2017

110

1 reference

17 September 2017

5

1 reference

17 September 2017

1096-1106

1 reference

Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture

17 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

Functional erythropoietin autocrine loop in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

The cellular biology of erythropoietin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

The erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin biology in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Emerging biological roles for erythropoietin in the nervous system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Expression patterns of erythropoietin and its receptor in the developing midbrain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Effects of erythropoietin on neuronal activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Prognostic significance of erythropoietin expression in human endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Understanding the presence and function of erythropoietin receptors on cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin to treat anaemia in patients with head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Expression of erythropoietin by the human placenta.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Gut peptide receptor expression in human pancreatic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Incidence of anemia in children with solid tumors or Hodgkin disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Recombinant human erythropoietin treatment for chemotherapy-related anemia in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Is epoetin alfa a treatment option for chemotherapy-related anemia in children?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Early epoetin alfa treatment in children with solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Polycythaemia and neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Neuroblastoma with expression of erythropoietin resulting in erythrocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22879

7 January 2021

Identifiers

DOI

10.1002/CNCR.22879

1 reference

17 September 2017

1 reference